Single-step fabrication of fibrous Si/Sn composite nanowire anodes by high-pressure He plasma sputtering for high-capacity Li-ion batteries

Abstract To realize high-capacity Si anodes for next-generation Li-ion batteries, Si/Sn nanowires were fabricated in a single-step procedure using He plasma sputtering at a high pressure of 100–500 mTorr without substrate heating. The Si/Sn nanowires consisted of an amorphous Si core and a crystalline Sn shell. Si/Sn composite nanowire films formed a spider-web-like network structure, a rod-like structure, or an aggregated structure of nanowires and nanoparticles depending on the conditions used in the plasma process. Anodes prepared with Si/Sn nanowire films with the spider-web-like network structure and the aggregated structure of nanowires and nanoparticles showed a high Li-storage capacity of 1219 and 977 mAh/g, respectively, for the initial 54 cycles at a C-rate of 0.01, and a capacity of 644 and 580 mAh/g, respectively, after 135 cycles at a C-rate of 0.1. The developed plasma sputtering process enabled us to form a binder-free high-capacity Si/Sn-nanowire anode via a simple single-step procedure

Additional file 2 of Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report

Supplementary Material 2: Vacuolation and anti-C4d-positive cardiomyocytes.tif. a: Vacuolation of the cardiomyocytes. b: anti-C4d immunohistochemistry-positive cardiomyocytes. The positivity is compatible with the vacuolatio

Additional file 1 of Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report

Supplementary Material 1: Macroscopic haemorrhage of the spleen and oesophagus.tif. a: macroscopic haemorrhage on the surface of the spleen. b: macroscopic haemorrhage on the mucosal surface of the oesophagu

Additional file 3 of Histopathologically TMA-like distribution of multiple organ thromboses following the initial dose of the BNT162b2 mRNA vaccine (Comirnaty, Pfizer/BioNTech): an autopsy case report

Supplementary Material 3: Ultrastructural analysis of microthrombi in the heart.tif. a to d: Microthrombi scanned by transmission electron microscopy. The nuclei of vascular endothelial cells and red blood cells are visible, and platelets and fibrin are found as the boundary indistinct area around the red blood cells with low electron density. The degree of occlusion varies; however, almost all thrombi are non-occlusive. The yellow arrowheads indicate the nuclei of the endothelium, the arrows indicate platelets, the stars indicate fibrin, and the red arrowheads indicate the erythrocyte

Correlation between ΔLDL-C (D0-D28) and ΔHCV core antigen (D0-D1).

<p>Scatterplots with fitting line show positive correlation between ΔLDL-C and ΔHCV core antigen. Pearson’s correlation provides coefficient (r) and p-value. Open circles: the LDV/SOF patients. Closed circles: the DCV/ASV patients.</p

Factors Associated with ΔLDL-C value with HCV administered IFN-free regimen, Analyzed by Linear Regression Analysis.

<p>Factors Associated with ΔLDL-C value with HCV administered IFN-free regimen, Analyzed by Linear Regression Analysis.</p

Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment

<div><p>Background & Aim</p><p>We performed lipid analyses at the early period of therapy in patients with chronic hepatitis C who underwent interferon (IFN)-free direct-acting antiviral (DAA) treatment, and we attempted to identify the factors that contributed to a rapid increase in the patients’ serum low-density lipoprotein cholesterol (LDL-C) concentration.</p><p>Methods</p><p>We retrospectively analyzed the cases of 100 consecutive patients with HCV infection treated at the National Hospital Organization Nagasaki Medical Center: 24 patients underwent daclatasvir (DCV) and asunaprevir (ASV) combination therapy (DCV/ASV) for 24 weeks, and the other 76 patients underwent ledipasvir and sofosbuvir combination therapy (LDV/SOF) for 12 weeks. ΔLDL-C was defined as the changed in LDL-C level at 28 days from the start of therapy. To determine whether ΔLDL-C was associated with several kinds of factors including viral kinetics, we performed a stepwise multiple linear regression analysis.</p><p>Results</p><p>The LDL-C levels in patients treated with LDV/SOF were markedly and significantly elevated (87.45 to 122.5 mg/dl; p<10⁻¹⁰) compared to those in the DCV/ASV-treated patients (80.15 to 87.8 mg/dl; p = 0.0056). The median levels of ΔLDL-C in the LDV/SOF and DCV/ASV groups were 33.2 and 13.1, respectively. LDV/SOF combination therapy as an IFN-free regimen (p<0.001) and ΔHCV core antigen (0–1 day drop) (p<0.044) were identified as independent factors that were closely related to the ΔLDL-C.</p><p>Conclusions</p><p>A rapid increase in the serum LDL-C concentration during the IFN-free treatment of hepatitis C was associated with the type of HCV therapy and a decline of HCV core protein.</p></div

Scatterplots and boxplots of ΔTC or ΔLDL-C levels after the administration of the IFN-free regimen.

<p>(a) Median changes of TC in each therapy. (b,c) Scatterplots and boxplots of ΔTC in the LDV/SOV patient group (b) and in the DCV/ASV group (c). (d) Median changes of LDL-C in each therapy. (e,f) Scatterplots and boxplots of ΔLDL-C in the LDV/SOF (e) and DCV/ASV (f) −groups. *p<0.001.</p